| KMDA Stock | | | ILA 2,140 26.00 1.20% |
Chairman
Mr. Leon Yehuda Recanati is Chairman of the Board of the company. He has served on our board of directors since May 2005 and has served as Chairman since March 7, 2013. Mr. Recanati currently serves as a board member of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange. He is also a board member of the following private companies GlenRock Israel Ltd., GlenRock Medical, Shellcase, Gov, Govli Financial Services Ltd., Govli Limited, Microbes Inc., RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Fund and Newbank Ltd. He is currently Chairman and Chief Executive Officer of GlenRock. Previously, Mr. Recanati was Chief Executive Officer andor Chairman of IDB Holding Corporation Clal Industries Ltd. Azorim Investment Development and Construction Co Ltd. Delek Israel Fuel Corporation and SuperSol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel since 2020.
| Age | 71 |
| Tenure | 4 years |
| Professional Marks | MBA |
| Phone | (972) 8 9406472 |
| Web | www.kamada.com |
Recanati holds an MBA degree from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.
Kamada Management Efficiency
Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities.
Kamada has accumulated 17.41
M in total debt with debt to equity ratio
(D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Kamada has a current ratio of 6.72, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kamada until it has trouble settling it off, either with new capital or with free cash flow. So, Kamada's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kamada sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kamada to invest in growth at high rates of return. When we think about Kamada's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CHAIRMAN Age |
| Yoav Doppelt | ICL Israel Chemicals | 51 |
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 408 people. Kamada (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 355 people.
Management Performance
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pnina Strauss, Vice President - Inhalation programs & IP | |
| Itzhak Krinsky, Director | |
| Lilach Topilsky, Chairman of the Board | |
| Ari Shamiss, Director | |
| Barak Bashari, Vice President - Operations | |
| Eran Schenker, Vice President - Medical Director | |
| Tuvia Shoham, Independent Director | |
| Eran Nir, Chief Officer | |
| Hanni Neheman, VP Sales | |
| Michal Stein, Vice President and Medical Director for Immunology | |
| Ariella Raban, VP HR | |
| Shani Dotan, Vice President of Human Resources | |
| Yael Brenner, Vice President - Quality | |
| Abraham Havron, Independent Director | |
| Ruth Wolfson, Senior Vice President - Scientific Affairs | |
| Shmuel Rubinstein, Director | |
| Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases | |
| Jon Knight, VP Operations | |
| Michael Berelowitz, Director | |
| David Tsur, Co-Founder and Deputy Executive Chairman | |
| Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D | |
| Leon Recanati, Chairman of the Board | |
| Jonathan Hahn, Director | |
| Gwen Melincoff, Director | |
| Chaime Orlev, Chief Financial Officer | |
| Michal Ayalon, Vice President - Research & Development | |
| Yifat Esq, Gen Legal | |
| Amir London, Chief Executive Officer | |
| Estery GilozRan, Independent Director | |
| Eitan Kyiet, Vice President - Business Development | |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Kamada Stock
When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock: Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For information on how to trade Kamada Stock refer to our
How to Trade Kamada Stock guide.
You can also try the
Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.